NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

脊髓小腦變性症(SCA)- 流行病學預測 2028年

Spinocerebellar Ataxia (SCA) - Epidemiology Forecast to 2028

出版商 DelveInsight Business Research LLP 商品編碼 909906
出版日期 按訂單生產 內容資訊 英文 80 Pages
商品交期: 2-10個工作天內
價格
脊髓小腦變性症(SCA)- 流行病學預測 2028年 Spinocerebellar Ataxia (SCA) - Epidemiology Forecast to 2028
出版日期: 按訂單生產內容資訊: 英文 80 Pages
簡介

主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的脊髓小腦變性症(SCA)在2018年患病數估算為4萬2,043人。

本報告提供主要7個國家(美國,英國,德國,法國,義大利,西班牙,日本)的脊髓小腦變性症(SCA)市場調查,市場及疾病概要,各國流行病學的預測,各病型的患病數及診斷數的轉變,未滿足需求等相關資訊。

目錄

第1章 重要洞察

第2章 疾病背景和概要

  • 簡介
  • 脊髓小腦變性症(SCA)的病型
    • 第1型(SCA1)
    • 第2型(SCA2)
    • 第3型(SCA3)
    • 第6型(SCA6)
    • 第7型(SCA7)
  • 原因和危險因素
  • 歷史
  • 徵兆與症狀
  • 病理生理學
  • 診斷
  • 生物標記
    • 神經成像生物標記物
    • 眼球運動生物標記
    • 生物學的生物標記

第3章 流行病學和患者人口

  • 主要調查結果
  • 主要7個國家的脊髓小腦變性症(SCA)的總患病數

第4章 脊髓小腦變性症(SCA)的流行病學:各國

  • 美國
    • 假設和根據
    • 總患病數
    • 總診斷數
    • 總患病數:各病型
  • 歐洲5個國家
    • 德國
      • 總患病數
      • 總診斷數
      • 總患病數:各病型
    • 法國
      • 總患病數
      • 總診斷數
      • 總患病數:各病型
    • 義大利
      • 總患病數
      • 總診斷數
      • 總患病數:各病型
    • 西班牙
      • 總患病數
      • 總診斷數
      • 總患病數:各病型
    • 英國
      • 總患病數
      • 總診斷數
      • 總患病數:各病型
  • 日本
    • 總患病數
    • 總診斷數
    • 總患病數:各病型

第5章 治療

  • 潛在性治療
  • 美國指南
    • 宿主組織的局部敏銳度
  • 歐洲的指南
  • 脊髓小腦變性症(SCA)的管理

第6章 未滿足需求

第7章 附錄

  • 調查手法

第8章 DelveInsight的服務內容

第9章 免責聲明

第10章 關於DelveInsight

目錄
Product Code: DIEI0377

DelveInsight's ‘Spinocerebellar Ataxia (SCA)- Epidemiology Forecast to 2028’ report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Spinocerebellar Ataxia in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2017-2028.

Disease Understanding:

Spinocerebellar Ataxia is a genetic disorder which is progressive, degenerative, and often fatal. The clinical marker of all SCAs is a progressive loss of balance and coordination accompanied by slurred speech. The mobility and communicative skills of individuals with an SCA are restricted, which strongly impairs quality of life, and many SCAs lead to premature death.

Spinocerebellar Ataxia Epidemiology:

The Spinocerebellar Ataxia (SCA) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Spinocerebellar Ataxia are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Spinocerebellar Ataxia Epidemiology Segmentation:

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population, total diagnosed cases of Spinocerebellar Ataxia and type-specific prevalent cases) scenario of Spinocerebellar Ataxia (SCA) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2028.

The DelveInsight report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

According to DelveInsight, the total number of prevalent cases of Spinocerebellar Ataxia (SCA) in 7 MM was found to be 42,043, in the year 2017.

Report Scope:

  • The report covers detailed overview of Spinocerebellar Ataxia explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Spinocerebellar Ataxia in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by prevalence of SCA, total diagnosed prevalence of Spinocerebellar Ataxia, incidence of Spinocerebellar Ataxia, and type-specific prevalent cases in 7MM

Key strengths:

  • 10 Year Forecast of Spinocerebellar Ataxia epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of SCA
  • Prevalent Cases according to segmentation: Prevalence, Diagnosed Cases, Type specific

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Disease Background and Overview

  • 2.1. Introduction
  • 2.2. Subtypes of SCA
    • 2.2.1. SCA1
    • 2.2.2. SCA2
    • 2.2.3. SCA3
    • 2.2.4. SCA6
    • 2.2.5. SCA7
  • 2.3. Causes and risk factors
  • 2.4. History
  • 2.5. Signs and Symptoms
  • 2.6. Pathophysiology
  • 2.7. Diagnosis
  • 2.8. Biomarkers
    • 2.8.1. Neuroimaging biomarkers
    • 2.8.2. Oculomotor biomarkers
    • 2.8.3. Biological biomarkers

3. Epidemiology and Patient Population

  • 3.1. Key Findings
  • 3.2. 7MM Total Patient Population of Spinocerebellar Ataxia

4. Country Wise-Epidemiology of Spinocerebellar Ataxia

  • 4.1. United States
    • 4.1.1. Assumptions and Rationale
    • 4.1.2. Total Prevalent Population of Spinocerebellar Ataxia in the United States
    • 4.1.3. Total Diagnosed Cases of Spinocerebellar Ataxia in the United States
    • 4.1.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the United States
  • 4.2. EU5 Countries
    • 4.2.1. Assumptions and Rationale
  • 4.3. Germany
    • 4.3.1. Total Prevalent Population of Spinocerebellar Ataxia in Germany
    • 4.3.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Germany
    • 4.3.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the Germany
  • 4.4. France
    • 4.4.1. Total Prevalent Population of Spinocerebellar Ataxia in France
    • 4.4.2. Total Diagnosed Cases of Spinocerebellar Ataxia in France
    • 4.4.3. Type-Specific Prevalence of Spinocerebellar Ataxia in France
  • 4.5. Italy
    • 4.5.1. Total Prevalent Population of Spinocerebellar Ataxia in Italy
    • 4.5.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Italy
    • 4.5.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Italy
  • 4.6. Spain
    • 4.6.1. Total Prevalent Population of Spinocerebellar Ataxia in Spain
    • 4.6.2. Total Diagnosed Cases of Spinocerebellar Ataxia in Spain
    • 4.6.3. Type-Specific Prevalence of Spinocerebellar Ataxia in Spain
  • 4.7. United Kingdom
    • 4.7.1. Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom
    • 4.7.2. Total Diagnosed Cases of Spinocerebellar Ataxia in the United Kingdom
    • 4.7.3. Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom
  • 4.8. Japan
    • 4.8.1. Assumptions and Rationale
    • 4.8.2. Total Prevalent Population of Spinocerebellar Ataxia in Japan
    • 4.8.3. Total Diagnosed Cases of Spinocerebellar Ataxia in Japan
    • 4.8.4. Type-Specific Prevalence of Spinocerebellar Ataxia in the Japan

5. Treatments

  • 5.1. Potential treatments
  • 5.2. U.S. Guidelines
    • 5.2.1. Local Susceptibility of Host Tissue
  • 5.3. Europe Guidelines
  • 5.4. Management of Spinocerebellar Ataxia

6. Unmet Needs

7. Appendix

  • 7.1. Report Methodology

8. DelveInsight Capabilities

9. Disclaimer

10. About DelveInsight

List of Tables

  • Table 1: SCA subtypes
  • Table 2: SCA subtypes with associated clinical signs
  • Table 3: Total Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Table 4: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 5: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 6: Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Table 7: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 8: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 9: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Table 10: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Table 11: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Table 12: Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Table 13: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 14: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 15: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Table 16: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 17: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Table 19: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 20: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 21: Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Table 22: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 23: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Table 24: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)

List of Figures

  • Figure 1: SCA subtypes overall prevalence
  • Figure 2: Repeat expansions that cause ataxia
  • Figure 3: Harding's classification of Spinocerebellar Ataxia, detailing the classification of SCA based on symptom presentation
  • Figure 4: Common disease mechanisms underlying SCAs.
  • Figure 5: Flowchart of molecular genetic diagnosis of SCAs
  • Figure 6: Total Prevalent Patient Population of Spinocerebellar Ataxia in the 7MM (2017-2028)
  • Figure 7: Total Prevalent Population of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 8: Total Diagnosed cases of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 9:Type-Specific Prevalence of Spinocerebellar Ataxia in the United States (2017-2028)
  • Figure 10: Total Prevalent Population of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 11: Total Diagnosed cases of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 12: Type-Specific Prevalence of Spinocerebellar Ataxia in Germany (2017-2028)
  • Figure 13: Total Prevalent Population of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 14: Total Diagnosed cases of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 15:Type-Specific Prevalence of Spinocerebellar Ataxia in France (2017-2028)
  • Figure 16: Total Prevalent Population of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 17: Total Diagnosed cases of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 18: Type-Specific Prevalence of Spinocerebellar Ataxia in Italy (2017-2028)
  • Figure 19: Total Prevalent Population of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 20: Total Diagnosed cases of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 21:Type-Specific Prevalence of Spinocerebellar Ataxia in Spain (2017-2028)
  • Figure 22: Total Prevalent Population of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 23: Total Diagnosed cases of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 24:Type-Specific Prevalence of Spinocerebellar Ataxia in the United Kingdom (2017-2028)
  • Figure 25: Total Prevalent Population of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 26: Total Diagnosed cases of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 27: Type-Specific Prevalence of Spinocerebellar Ataxia in Japan (2017-2028)
  • Figure 28: Unmet Needs of Spinocerebellar ataxia